JESSICA TOWNLEY: Open Payments
NPI 1265078547 · ALEXANDRIA, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,217 in 69 payments from 16 companies in 2025. Trend: 2023 $1,687 · 2024 $1,226 · 2025 $1,217
Food & beverage: $1,217
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $271 |
| Novo Nordisk Inc | 13 | $196 |
| AstraZeneca Pharmaceuticals LP | 7 | $161 |
| Sumitomo Pharma America, Inc. | 5 | $122 |
| Lilly USA, LLC | 6 | $108 |
| Otsuka America Pharmaceutical, Inc. | 4 | $80 |
| Corcept Therapeutics | 3 | $50 |
| Axsome Therapeutics, Inc. | 2 | $42 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $35 |
| Amgen Inc. | 2 | $28 |
Products named: QULIPTA, GEMTESA, MOUNJARO, REXULTI, Wegovy, VRAYLAR, AIRSUPRA, FARXIGA.
Industry payments across LA — which companies pay providers there.
